NYSE:MRK - Merck & Co., Inc. Stock Price, Price Target & More

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc. announced a quarterly dividend on Tuesday, May 22nd. Stockholders of record on Friday, June 15th will be paid a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 annualized dividend and a dividend yield of 3.15%. The ex-dividend date of this dividend is Thursday, June 14th. View Merck & Co., Inc.'s Dividend History.

Merck & Co., Inc. declared that its board has approved a stock buyback program on Saturday, December 2nd 2017, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings results on Tuesday, May, 1st. The company reported $1.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.05. The business had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $10.09 billion. Merck & Co., Inc. had a return on equity of 30.93% and a net margin of 4.31%. The firm's revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.88 EPS. View Merck & Co., Inc.'s Earnings History.

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co., Inc..

Merck & Co., Inc. issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

18 brokers have issued 1 year price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $56.00 to $72.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $65.8644 in the next twelve months. View Analyst Ratings for Merck & Co., Inc..

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Sanofi (SNY), Bayer (BAYRY), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

Media stories about MRK stock have been trending somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Merck & Co., Inc. earned a daily sentiment score of 0.08 on Accern's scale. They also assigned media stories about the company an impact score of 46.11 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Merck & Co., Inc.'s stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.85%), Franklin Resources Inc. (1.82%), Northern Trust Corp (1.24%), Boston Partners (0.55%), Legal & General Group Plc (0.50%) and Barrow Hanley Mewhinney & Strauss LLC (0.47%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Federated Investors Inc. PA, Northern Trust Corp, Boston Partners, Barrow Hanley Mewhinney & Strauss LLC, Swiss National Bank, Independent Franchise Partners LLP and Legal & General Group Plc. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

MRK stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Pzena Investment Management LLC, Natixis, Manning & Napier Group LLC, Levin Capital Strategies L.P., American Century Companies Inc., Sound Shore Management Inc. CT and Summit Trail Advisors LLC. View Insider Buying and Selling for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $60.91.

Merck & Co., Inc. has a market capitalization of $165.73 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]